Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethacridine is an acridine derivative primarily used as a topical antiseptic and as an abortifacient agent. As an antiseptic, it is effective mainly against Gram-positive bacteria such as Streptococci and Staphylococci, but less so against Gram-negative bacteria. It is commonly applied in 0.1% solutions for the treatment of purulent skin infections, infected mucous membranes, wounds (including those that are difficult to heal), genital inflammation, oral infections, and skin abrasions[1][8]. Ethacridine's mechanism of action involves binding to bacterial DNA and inhibiting microbial protein synthesis by preventing DNA and RNA synthesis within the cell[8]. In obstetrics, it has been used for second-trimester abortion via extra-amniotic or intra-amniotic instillation; this method is considered safer than hypertonic saline[1][5]. Recent research also suggests that ethacridine can inactivate viral particles such as SARS-CoV-2 by preventing their binding to host cells[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethacridine.